分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

DNMT3A low-expression is correlated to poor prognosis in childhood B-ALL and confers resistance to daunorubicin on leukemic cells

Li Weijing, Liu Shuguang, Wang Chanjuan, Cui Lei, Zhao Xiaoxi, Liu Wei, Zhang Ruidong, Li Zhigang

Journal:BMC CANCER

IF:3.8

DOI:10.1186/s12885-023-10724-6

PMID:36934225

Published:2023-03-18

research field:肿瘤学分子生物学血液学

Abstract

Background Little is known about DNMT3A expression and its prognostic significance in childhood B cell acute lymphoblastic leukemia (B-ALL). Methods We determined DNMT3A mRNA expression in 102 children with B-ALL. Correlations with relapse-free survival (RFS) and common clinical characteristics were analyzed. DNMT3A was stably knocked out by CRISPR/Cas9 gene editing technology in Reh and 697 B-ALL cell lines. Cell proliferation activity after treated with daunorubicin (DNR) was determined by CCK8 assay in DNMT3A KO Reh and 697 cell lines. Results DNMT3A expression in B-ALL patients who were in continuous complete remission (CCR) was higher than in those who got relapse ( P  = 0.0111). Receiver operating characteristic curve showed prognostic significance of DNMT3A expression ( P  = 0.003). Low expression of DNMT3A (≤ 0.197) was significantly correlated with poor RFS ( P  < 0.001) in children with B-ALL. Knock-out of DNMT3A in Reh and 697 cell lines significantly increased IC50 of DNR ( P  = 0.0201 and 0.0022 respectively), indicating elevated resistance to DNR. Conclusion Low expression of DNMT3A associates with poor prognosis in children with B-ALL. Knock-out of DNMT3A confers resistance to DNR on leukemic cells.

本文使用的Yeasen产品

相关产品
购物车
客服
转染试用